Candida vaginitis during contraceptive use: The influence of methods, antifungal susceptibility and virulence patterns

References

• Baeten JM, Nyange PM, Richardson BA, Lavreys L Chohan B, Martin HL Jr et al. 2001. Hormonal contraception and risk of sexually-transmitted disease acquisition: results from a prospective study. American Journal of Obstetrics and Gynecology 185:380–385.
   PubMed Web of Science ®Google Scholar
• Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. 2004. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstetrics and Gynecology 104:926–930.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Sobel JD, Nailor MD. 2011. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction-impact of two decades. Mycoses 54:34–38.
   PubMed Web of Science ®Google Scholar
• Ceruti M, Canestrelli M, Condemi V, Piantelli G, de Paolis P, Amone F et al. 1994. Methods of contraception and rates of genital infections. Clinical and Experimental Obstetrics and Gynecology 21:119–123.
   PubMedGoogle Scholar
• Cetin AM, Ocak S, Gungoren A, Hakverdi AU. 2007. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scandinavian Journal of Infectious Diseases 39:584–588.
   PubMed Web of Science ®Google Scholar
• Chassot F, Negri MF, Svidzinski AE, Donatti L, Peralta RM, Svidzinski TI et al. 2008. Can uterine contraceptive devices be a Candida albicans reservoir?Contraception 77:355–359.
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institution. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard CLSI document M27-A3. Wayne, PA: CLSI.
   Google Scholar
• Danby CS, Boikov D, Rautemaa-Richardson D, Sobel JD. 2012. Effect of pH on in vitro and susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrobial Agents and Chemotherapy 56:1403–1406.
   PubMed Web of Science ®Google Scholar
• de Oliveira JM, Cruz AS, Fonseca AF, Vaz CP, Rodrigues A, Aurea F et al. 1993. Prevalence of Candida albicans in vaginal fluid of asymptomatic Portuguese women. Journal of Reproductive Medicine 38:41–42.
   PubMedGoogle Scholar
• Donders GG, Bellen G, Mendling W. 2010. Management of recurrent vulvo-vaginal candidosis as a recurrent illness. Gynecologic and Obstetric Investigation 70:306–321.
   PubMed Web of Science ®Google Scholar
• Donders GG, Berger J, Heuninckx H, Bellen G, Cornelis A. 2011a. Vaginal flora changes on Pap smears after insertion of intrauterine levonorgestrel-releasing device (Mirena®). Contraception 83:352–356.
   PubMed Web of Science ®Google Scholar
• Donders GG, Mertens I, Bellen G, Pelckmans S. 2011b. Self-elimination of risk factors for recurrent vulvovaginal candidiasis. Mycoses 54:39–45.
   PubMedGoogle Scholar
• Fan SR, Liu XP. 2011. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 54:501–505.
   PubMed Web of Science ®Google Scholar
• FDA. 2011. Family planning evidence-based guidance developed through worldwide collaboration: A WHO family planning cornerstone. Available at: www.fda.gov/forconsumers/byaudience/forwomen/ucm118465.html
   Google Scholar
• Geiger AM, Foxman B. 1996. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 7:182–187.
   PubMed Web of Science ®Google Scholar
• Guzel AB, Ilkit M, Akar T, Burgut R, Demir SC. 2011a. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of yeast species. Medical Mycology 49:16–25.
   PubMed Web of Science ®Google Scholar
• Guzel AB, Ilkit M, Burgut R, Urunsak IF, Ozgunen FT. 2011b. An evaluation of risk factors in pregnant women with Candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling. Mycopathologia 172:25–36.
   PubMedGoogle Scholar
• Hodoglugil NN, Aslan D, Bertan M. 2000. Intrauterine device use and some issues related to sexual transmitted disease screening and occurrence. Contraception 61:359–364.
   PubMed Web of Science ®Google Scholar
• Ilkit M, Guzel AB. 2011. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. Critical Reviews in Microbiology 37:250–261.
   PubMed Web of Science ®Google Scholar
• Kalkancı A, Güzel AB, IIJ Khalil, Aydın M, Ilkit M, Kustimur S. 2012. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Medical Mycology 50:585–593.
   PubMed Web of Science ®Google Scholar
• Luo G, Samaranayake LP, Yau JY. 2001. Candida species exhibit differential in vitro hemolytic activities. Journal of Clinical Microbiology 39: 2971–2974.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD. 2003. Vulvovaginal candidiasis. Obstetrics and Gynecology Clinics of North America 30:671–684.
   PubMedGoogle Scholar
• Ozcan K, Ilkit M, Ates A, Turac-Bicer A, Demirhindi H. 2010. Performance of Chromogenic Candida agar and CHROMagar Candida in recovery and presumptive identification of monofungal and polyfungal vaginal isolates. Medical Mycology 48:29–34.
   PubMed Web of Science ®Google Scholar
• Parewijck W, Claeys G, Thiery M, van Kets H. 1988. Candidiasis in women fitted with an intrauterine contraceptive device. British Journal of Obstetrics and Gynaecology 95:408–410.
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR et al.;The CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.Drug Resistance Updates 13:180–195.
   PubMed Web of Science ®Google Scholar
• Price MF, Wilkinson ID, Gentry LO. 1982. Plate method for detection of phospholipase activity in Candida albicans. Sabouradia 20:7–14.
   PubMedGoogle Scholar
• Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. Journal of Clinical Microbiology 43:2155–2162.
   PubMed Web of Science ®Google Scholar
• Romeo O, Criseo G. 2011. Candida africana and its closest relatives. Mycoses 54:475–486.
   PubMed Web of Science ®Google Scholar
• Roy S. 1991. Nonbarrier contraceptives and vaginitis and vaginosis. American Journal of Obstetrics and Gynecology 165:1240–1244.
   PubMed Web of Science ®Google Scholar
• Rüchel R, Böning B, Borg M. 1986. Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme during infection in vitro. Infection and Immunity 53:411–419.
   PubMed Web of Science ®Google Scholar
• Turin L, Riva F, Galbiati G, Cainelli T. 2000. Fast, simple and highly sensitive double-rounded polymerase chain reaction assay to detect medically relevant fungi in dermatological specimens. European Journal of Clinical Investigation 30:511–518.
   PubMed Web of Science ®Google Scholar
• Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. 2012. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiology Reviews 36:288–305.
   PubMed Web of Science ®Google Scholar
• Sobel JD. 2007. Vulvaginal candidosis. Lancet 369:1961–1971.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Chaim W. 1997. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clinical Infectious Diseases 24:649–652.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Chaim W, Nagappan V, Leaman D. 2003. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. American Journal of Obstetrics and Gynecology 189:1297.
   PubMed Web of Science ®Google Scholar
• Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A, Monaco A. 1995. The impact of oral contraception on vulvovaginal candidiasis. Contraception 51:293–297.
   PubMed Web of Science ®Google Scholar
• Spinillo A, Pizzoli G, Colonna L, Nicola S, de Seta F, Guaschino S. 1993. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstetrics and Gynecology 81:721–727.
   PubMed Web of Science ®Google Scholar
• Veres S, Miller L, Burington B. 2004. A comparison between the vaginal ring and oral contraceptives. Obstetrics and Gynecology 104:555–563.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Takano M, Murakami M, Tanaka H, Matsuhisa A, Nakao N et al. 1999. Characterization of a hemolytic factor from Candida albicans. Microbiology 145:689–694.
   PubMed Web of Science ®Google Scholar